As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
18 Analysts have issued a REGENXBIO, Inc. forecast:
18 Analysts have issued a REGENXBIO, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 156 156 |
75%
75%
|
|
Gross Profit | 128 128 |
154%
154%
|
|
EBITDA | -149 -149 |
35%
35%
|
EBIT (Operating Income) EBIT | -165 -165 |
33%
33%
|
Net Profit | -176 -176 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Curran Simpson |
Employees | 353 |
Founded | 2008 |
Website | regenxbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.